Abstract

Alternative splicing events (ASEs) play a role in cancer development and progression. We investigated whether ASEs are prognostic for overall survival (OS) in hepatocellular carcinoma (HCC). RNA sequencing data was obtained for 343 patients included in The Cancer Genome Atlas. Matched splicing event data for these patients was then obtained from the TCGASpliceSeq database, which includes data for seven types of ASEs. Univariate and multivariate Cox regression analysis demonstrated that 3,814 OS-associated splicing events (OS-SEs) were correlated with OS. Prognostic indices were developed based on the most significant OS-SEs. The prognostic index based on all seven types of ASEs (PI-ALL) demonstrated superior efficacy in predicting OS of HCC patients at 2,000 days compared to those based on single ASE types. Patients were stratified into two risk groups (high and low) based on the median prognostic index. Kaplan-Meier survival analysis demonstrated that PI-ALL had the greatest capacity to distinguish between patients with favorable vs. poor outcomes. Finally, univariate Cox regression analysis demonstrated that the expression of 23 splicing factors was correlated with OS-SEs in the HCC cohort. Our data indicate that a prognostic index based on ASEs is prognostic for OS in HCC.

Highlights

  • Alternative splicing (AS) is an important posttranscriptional regulatory mechanism that increases protein diversity [1]

  • We analyzed alternative splicing event (ASE) in pooled mRNA samples from 343 hepatocellular carcinoma (HCC) cases included in the The Cancer Genome Atlas (TCGA) dataset

  • A total of 34,163 ASEs in 8,985 genes were identified in the cohort of HCC cases: 2,666 alternate acceptor site (AA) events in 1,937 genes, 2,331 alternate donor site (AD) events in 1,663 genes, 6,352 alternate promoter (AP) events in 2,566 genes, 8,087 alternate terminator (AT) events in 3,532 genes, 12,327 exon skip (ES) events in 5,343 genes, 137 mutually exclusive exons (ME) events in 135 genes, and 2,263 retained intron (RI) events in 1,561 genes (Table 1)

Read more

Summary

Introduction

Alternative splicing (AS) is an important posttranscriptional regulatory mechanism that increases protein diversity [1]. AS of pre-mRNA transcribed from a single gene can generate isoforms with distinct structures and functions [2]. 95% of the genes in the human genome undergo AS [3]. Aberrant AS can play a role in cancer development and resistance to therapy [2, 4,5,6]. Splicing factor mutations or alterations in expression can result in the activation of oncogenes and signaling pathways that promote tumorigenesis [7,8,9,10]. Alterative splicing events (ASEs) could function as diagnostic or prognostic biomarkers in various cancers. Cancer-specific splice isoforms or splicing factors could be therapeutic targets

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call